Identifying Resistance Mechanisms Of Targeted BRAF Inhibitors In Metastatic Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$379,015.00
Summary
Late-stage melanoma is an aggressive skin cancer for which traditional treatment strategies such as chemotherapy are ineffective. Recently, a new class of targeted drugs (BRAF inhibitors) has become the standard of care for a subset of melanoma patients; however, long term treatment success is complicated by drug resistance. This study will identify the causes of resistance with the purpose to improve targeted drug strategies and increase survival rates for late-stage melanoma patients.
Adequate nutrition is necessary for recovery from illness. 30-40% of hospitalised patients may be malnourished. The critically ill are at higher risk because of increased energy requirements yet often receive less than 50% of required nutritional intake. Adequate nutrition therapy is associated with improved patient outcomes, such as reduced mortality and reduced infectious complications. Robust strategies to implement of evidence-based recommendations for nutrition therapy are required.